Chiretta: Fever and Traditional Antimalarial Use

Fever is chiretta’s oldest and single most important classical claim, and it is the one claim across this herb’s four Benefits pages where a wrong answer has the shortest fuse. In classical Ayurveda, jvara — fever, above all the recurring and intermittent kind — is chiretta’s central indication, the reason it is a kirātatikta and not just another bitter tonic. In the temperate Himalayan foothills where Swertia chirayita grows, a recurring fever historically meant one disease before any other: malaria. Every other benefit claimed for chiretta carries a gap between tradition and proof. This is the only one where that gap sits directly beside a disease that can kill an adult within one or two days of the first serious symptom.

Taken on its own, Swertia chirayita has never been tested against fever or malaria in a human being. What exists is rodent antipyretic screening and cell-culture or infected-mouse antiplasmodial screening — real pharmacology, competently done in places, but two full steps removed from a person standing in a clinic with a temperature. That is the whole of the direct evidence, and it is thin.

Chiretta’s one genuine contact with modern clinical-trial infrastructure runs through a different door. It is one of four botanicals in AYUSH-64, a polyherbal formula that does have real, randomised, meta-analysed human trial data behind it — not for malaria, the indication the formula was actually built for, but for COVID-19, a disease with no traditional connection to chiretta, to fever formulas, or to Ayurveda’s fever theory at all. And when researchers took AYUSH-64’s four ingredients apart and tested them separately in the animal model closest to that COVID-19 programme, the antiviral credit went to a different plant. Chiretta’s own fraction showed immune activity without controlling the infection. This page tells that story in full, in order, because it is the most precisely documented case of formula substitution on this site — and it closes with the safety point that actually matters most: none of this, not the tradition and not the trial data, makes chiretta or AYUSH-64 a treatment for a real, dangerous fever.

Table of Contents

  1. The Claim and Where It Comes From
  2. Rodent and Cell-Culture Evidence for Chiretta Alone
  3. The Formula That Actually Has Human Data: AYUSH-64
  4. Malaria: One 1996 Note, and Why It Doesn’t Hold Up
  5. COVID-19: Real, Modest, Meta-Analysed Human Evidence
  6. The Component Study That Settles Attribution
  7. Why None of This Is a Treatment for Dangerous Fever
  8. What Is Not Known: A Numbered List
  9. Verdict and Evidence Tier
  10. Key Research Papers
  11. Connections

The Claim and Where It Comes From

Jvara — fever — is chiretta’s central classical Ayurvedic indication, ahead of the digestive, liver and blood-sugar claims covered on the other three pages in this set. Classical texts describe it specifically for recurrent and intermittent fevers, the pattern that in pre-modern South Asia was the clinical signature of malaria long before the parasite itself was identified under a microscope. Chiretta earned its Sanskrit epithet kirātatikta — “the bitter herb of the Kirātas,” a Himalayan hill people — in exactly this context: a bitter, whole-plant decoction taken for the region’s endemic recurring fevers.

The claim is not confined to household use. Chiretta appears in named classical fever formulas, most familiarly the Sudarshan and Mahasudarshan churna family, multi-herb bitter preparations still sold today for fever and general malaise. And it is one of four botanicals — alongside Alstonia scholaris, Caesalpinia crista and Picrorhiza kurroa — in AYUSH-64, a polyherbal formula originally developed by India’s Central Council for Research in Ayurvedic Sciences (CCRAS) specifically as an antimalarial. AYUSH-64 is the thread this whole page follows, because it is the only place chiretta’s fever claim ever reached anything resembling a modern clinical-trial programme.

Two claims are therefore bundled under “fever and antimalarial use,” and they need to be kept separate from the first sentence onward: chiretta as a standalone antipyretic and antimalarial, which is the folk and classical claim, and AYUSH-64 as a formula-level antimalarial and, much later, an adjunct COVID-19 treatment, which is where the actual clinical-trial record lives. Conflating the two — crediting chiretta with whatever AYUSH-64 has been shown to do — is the exact error this page is built to prevent, and the rest of it works through why.

Rodent and Cell-Culture Evidence for Chiretta Alone

Two separate pharmacological literatures sit under the fever claim, and both stop at the animal or the culture dish.

Antipyretic screening. The standard design gives rats or mice a fever-inducing agent — classically brewer’s yeast injected under the skin, which reliably raises body temperature for several hours — and then measures how far a plant extract brings the temperature back down against a paracetamol or aspirin comparator. Swertia extracts have reported activity in this design. It is a legitimate first-pass screen; it is not evidence that a person with a fever, of whatever cause, will benefit from the same extract.

Antiplasmodial screening. The parallel literature tests extracts and isolated compounds directly against Plasmodium parasites, either in culture or in mice infected with the rodent malaria species Plasmodium berghei. This is where chiretta’s evidence is least thin. Patel and colleagues, publishing in Future Microbiology in 2022, reported that swertiamarin altered immune responses in mice infected with Plasmodium berghei and conferred measurable protection. That is worth stating plainly and crediting: it is chiretta-specific — swertiamarin is one of the plant’s own signature secoiridoids, not a compound borrowed from elsewhere in the genus — and it is a real, if early-stage, positive finding in an infected-animal model, a step beyond a culture dish. It is not a human finding, and immune modulation that confers “some protection” in a mouse is a long way from clearing a Plasmodium falciparum infection in a person.

Now run the plainest possible search and see what it actually returns. A search for chiretta and antipyretic activity is the obvious first query anyone checking this claim would type. Doing it honestly matters more than describing it in the abstract: of the results on the first page, only a minority are unambiguously about Swertia chirayita under its current name; a couple more use the older synonym Swertia chirata — the same plant under a different name, so those genuinely do count — and the majority concern other species in the genus entirely, with S. punicea, S. macrosperma, S. longifolia and S. mussotii all appearing on the first page. At least one of the S. chirayita-labelled results is not an antipyretic pharmacology study at all, but a plant-biology paper on comparative photosynthetic gene expression that happens to use the species name. This is the same genus-wide species-substitution problem flagged on the Benefits hub: Swertia is a genus of more than a hundred species sharing overlapping marker compounds and overlapping common names, and a query built around the famous species routinely pulls in results about its cheaper, better-studied, or simply more numerous relatives. A reader who stops at the result count, without opening each abstract and checking the binomial, will overestimate how much antipyretic evidence exists for chiretta specifically.

Back to Table of Contents

The Formula That Actually Has Human Data: AYUSH-64

Before crediting or discrediting a herb on the strength of a commercial or classical formula, this site’s evidence doctrine requires checking one thing first: is the herb actually in the formula? Polyherbal names and marketing copy are not reliable here — elsewhere in this site’s herb coverage, a formula’s headline ingredient has turned out to be absent from its own recipe. AYUSH-64 is the opposite case, and it is worth stating clearly because the rest of this page depends on it: chiretta is genuinely, confirmedly one of AYUSH-64’s four ingredients.

The composition is not taken from a marketing page. It comes from the methods section of a 2023 primary research paper — Rizvi and colleagues, testing the formula in a Syrian hamster model, discussed in full below — which states the four botanicals directly: Alstonia scholaris (bark), Caesalpinia crista (seeds), Picrorhiza kurroa (rhizome) and Swertia chirata (whole plant). “Swertia chirata” is chiretta under its older botanical synonym — the same plant this whole page and the rest of the Chiretta Benefits set are about, not a different species slipped in under a similar name.

AYUSH-64 was developed by India’s Central Council for Research in Ayurvedic Sciences and formulated specifically as an antimalarial, drawing on the classical antipyretic and antiperiodic reputations of its four component herbs — chiretta’s fever indication among them. That original indication is covered next, and it is where the formula’s clinical record is weakest. The formula’s real clinical record turns out to belong to a completely different, much later indication, covered in the section after that.

Back to Table of Contents

Malaria: One 1996 Note, and Why It Doesn’t Hold Up

This site’s doctrine refuses to assert an efficacy number it cannot stand behind, and says so plainly rather than quietly rounding up. Here is that refusal, stated in advance: this page will not give you a cure rate, a parasite-clearance percentage, or any other efficacy figure for AYUSH-64 against malaria. The reason is simple — the primary human record does not support calculating one.

The retrievable primary source for AYUSH-64’s original antimalarial indication is a single item: Ali, “‘Ayush-64’ — a new anti-malarial herbal compound,” Indian Journal of Pathology & Microbiology, 1996. It runs two pages, 499 to 500, and PubMed’s own record for it carries no abstract at all. There is, in other words, essentially nothing here to appraise: no stated sample size to weigh, no stated control arm to check, no stated outcome measure to trust or distrust. A two-page, abstract-less 1996 note is not a clinical trial in any sense that would let a reader bound an effect size the way this site does for a drug-class mechanism elsewhere — there is no effect size in it at all. It survives in the literature as a historical marker that the formula was tried for malaria, not as evidence that it worked.

The second source is a genuine review, and it deserves to be read for exactly what it says and no further. Willcox, writing in Planta Medica in 2011, surveyed “improved traditional phytomedicines in current use for the clinical treatment of malaria” and identified six that were, at the time, government-approved in at least one country and used at meaningful scale: Artemisia annua, Cinchona bark, Cryptolepis sanguinolenta, AYUSH-64, “Malarial-5,” and Cochlospermum planchonii — with a seventh, an Argemone mexicana decoction, noted as still under development. Read that sentence carefully, because it is easy to overstate. Appearing on this list means AYUSH-64 achieved formal regulatory recognition in at least one jurisdiction and was judged worth including in a systematic review of the field. It does not mean the review is certifying that AYUSH-64 cures or reliably treats malaria — Willcox’s paper is a survey of what is approved and in current use, not a meta-analysis of efficacy outcomes, and this page does not have access to whatever primary efficacy data, if any, sits behind that regulatory approval. Saying more than that would be exactly the kind of confident overstatement this site’s doctrine exists to prevent, so this page stops here: AYUSH-64 has regulatory history as an antimalarial; on the evidence available to this page, it does not have an appraisable efficacy record as one.

Back to Table of Contents

COVID-19: Real, Modest, Meta-Analysed Human Evidence — For the Formula, Not the Herb

This is the part of chiretta’s story that is easy to miss, because it sits under a disease with no traditional connection to the herb at all. During the COVID-19 pandemic, AYUSH-64 was repurposed and tested as an add-on to standard care for mild-to-moderate disease — and here, unlike the malaria record, there is a real body of controlled human trial evidence. It should not be undersold to make the argument later in this section land harder; at the formula level, it is genuinely one of the better-supported claims anywhere across the Chiretta Benefits set.

The largest trial. Chopra and colleagues ran a 140-patient, multicentric, randomised controlled trial — AYUSH-64 plus standard of care against standard of care alone in mild and moderate COVID-19, published in PLoS ONE in 2023. The reported mean time to clinical recovery was 6.45 days in the AYUSH-64 arm against 8.26 days on standard care alone, a statistically significant difference (p = 0.003). Roughly a day and three-quarters off the recovery time, in a properly randomised, multicentric, adequately described trial, is a real result.

A second, independent randomised trial came out of Chandigarh: Singh and colleagues’ open-label randomised controlled trial of AYUSH-64 as an adjunct to standard care in mild-to-moderate COVID-19, published in Complementary Therapies in Medicine in 2022. It is a second data point in the same direction, from a different investigator group and a different city.

The result is not uniform, and the mixed data point deserves equal billing rather than a footnote. Thakar and colleagues ran a smaller open-label pilot study — AYUSH-64 adjunctive to standard of care in mild COVID-19, published in the Journal of Ayurveda and Integrative Medicine in 2022 — and found no statistically significant difference between arms on its primary outcome, the WHO clinical ordinal scale (p = 0.32), while symptom duration trended shorter in the AYUSH-64 group. The authors’ own conclusion described the findings as “inconclusive” on major outcomes such as mortality, oxygen use and ventilator need, given how few of those events occurred in a pilot-sized sample. That is an honest, appropriately hedged conclusion from the trial’s own authors, and this page repeats it rather than quietly dropping the one negative-leaning result from an otherwise positive-looking set.

Pooling the trials. The same Thakar research group later ran a living systematic review and meta-analysis — AYUSH therapeutics for COVID-19: a living systematic review and meta-analysis, published in the Journal of Integrative and Complementary Medicine in 2023 — and reported, using GRADE methodology, that add-on AYUSH-64 “likely provides therapeutic benefit” by reducing time to symptom resolution, with a pooled mean difference of 2.35 days lower (95% confidence interval: 4.05 days lower to 0.65 days lower) than standard care alone. A confidence interval that does not cross zero, built from GRADE-rated pooled data across several trials — including the pilot’s null result, folded in rather than discarded — is about as solid as this literature gets.

A caution on trial quality, from inside the same research community. Chaudhari and Somvanshi published a methodological analysis of CTRI-registered Ayurveda COVID-19 trials in 2023 and found that, despite a genuine surge in registered trials, overall methodological quality was “not up to the mark,” citing gaps in randomisation disclosure, blinding and sample-size justification across the field. That caution applies to the AYUSH-64 trial base too, and it is why this page calls the evidence modest rather than definitive, even while calling it real.

Context from outside the AYUSH programme. Diantini and colleagues reviewed randomised controlled trials of add-on plant-based COVID-19 therapies more broadly in 2023, covering twenty-two medicinal plants, and found Andrographis paniculata — the unrelated plant most often confused with chiretta — showing the best efficacy and confirmed safety among the plants reviewed. That is a small, almost wry detail worth sitting with: in a head-to-head review of botanical COVID-19 add-ons, the herb that comes out on top is the one people reach for by mistake when they actually meant chiretta.

What all of this is evidence for. Real, modest, positive, meta-analysed human trial data for AYUSH-64 as an add-on treatment in mild-to-moderate COVID-19. It is not evidence for chiretta as an antipyretic. It is not evidence for chiretta, or AYUSH-64, against malaria. COVID-19 has no traditional connection to jvara, to the Sudarshan churna fever formulas, or to any part of chiretta’s classical indication. The formula that happens to contain chiretta was tested, by historical circumstance, against a disease chiretta was never used for.

Back to Table of Contents

The Component Study That Settles Attribution

Everything above sets up the one finding that actually answers the question this page is organised around: when AYUSH-64 does something real, which of its four ingredients is doing it?

Rizvi and colleagues answered that directly in 2023, in a study published in Pharmaceuticals testing AYUSH-64 as a whole formula and its four ingredients separately in a Syrian hamster model of SARS-CoV-2 infection — the animal model closest in kind to the disease the human COVID-19 trials above were run against. This is exactly the design the gap between the malaria record and the COVID-19 trials calls for: not another test of the whole formula, but a test that can assign credit among its parts.

The result, in the study’s own terms: “the hamster challenge data showed robust anti-viral and immunomodulatory potential in A. scholaris, followed by P. kurroa. However, C. crista and S. chirata of A64 showed prominent immunomodulatory potential without limiting the lung viral load.” Translated: Alstonia scholaris bark, alone, controlled the actual viral infection and modulated immune activity. Picrorhiza kurroa showed a real but smaller antiviral effect. Chiretta — Swertia chirata — and Caesalpinia crista modulated the immune response without doing anything measurable to the amount of virus in the lungs. Immune modulation without viral control is not nothing, but it is not the antiviral effect that a disease-relevant outcome like faster clinical recovery would actually depend on.

The same paper’s in-vitro work reinforces the split at the cellular level: T-cell differentiation assays showed Alstonia scholaris causing a more profound suppression of Th1, Th2 and Th17 cell differentiation than either the complete AYUSH-64 formula or any of the other three ingredients tested alone. The whole formula’s immunomodulatory signature, in other words, looks like it is being driven predominantly by one of its four components — and it is not chiretta.

Why this is the single most important research finding on this page. Section by section, this page has shown: a real, modest, positive, meta-analysed body of human trial evidence exists for AYUSH-64 in COVID-19; that evidence sits at the formula level, not the single-herb level, which is already a reason for caution before crediting chiretta; and now, the one study that actually pulled the formula apart and tested its components separately found that the antiviral activity — the property the human trials’ clinical-recovery endpoint plausibly depends on — belongs to Alstonia scholaris, not to chiretta. Chiretta’s own fraction did something real (immune modulation), but not the thing that best explains the days-shorter recovery time seen in the human trials. Crediting AYUSH-64’s COVID-19 results to “chiretta” is formula substitution in its most precisely falsified form — not a vague suspicion that a whole-formula result probably belongs to some other ingredient, but a named component study saying, in its own words, which specific different plant the antiviral credit belongs to.

Back to Table of Contents

Why None of This Is a Treatment for Malaria or Dangerous Fever

🔴 Read this section even if you skipped everything above it. It is the most important paragraph on this page — more important than any research finding discussed so far.

Nothing in the preceding sections — not the rodent antipyretic data, not the mouse-model antiplasmodial finding, not AYUSH-64’s real and respectable COVID-19 trial record, not even a hypothetical future trial that vindicated chiretta’s classical fever use — changes the one fact that actually matters at the bedside: chiretta and AYUSH-64 are not diagnostic tools, and a bitter herb cannot tell you what is causing a fever.

Plasmodium falciparum malaria can progress from an ordinary-feeling fever to cerebral malaria, organ failure and death within one to two days. That is not a worst-case outlier; it is the ordinary natural history of untreated severe falciparum disease, which is why malaria remains a medical emergency everywhere it is endemic. A fever that might be malaria — which in practice means any fever arising during or after time spent in a malaria-endemic area — needs a blood film or a rapid diagnostic test, and, if that test is positive, prompt treatment with an artemisinin-based combination therapy (ACT). It does not need a bitter Himalayan herb, and it does not need a polyherbal formula whose best supporting clinical evidence, described in full above, comes from an entirely different disease. Delay in reaching diagnosis and treatment is one of the most consistently documented predictors of a bad malaria outcome — the danger is not hypothetical, and it is not specific to chiretta; it is what happens whenever any unproven remedy, herbal or otherwise, substitutes for diagnosis in a time-critical infection.

The same logic, at lower stakes but still real, applies to any high or persistent fever of unknown cause that is not self-evidently a minor viral illness: it needs to be evaluated, not self-treated with a bitter tonic on the strength of a classical reputation. Chiretta’s traditional fever indication is a real historical fact about what people did before diagnostic testing existed. It is not a modern treatment recommendation, and nothing in this page’s review of the evidence — including the genuinely positive AYUSH-64 COVID-19 data — changes that. If you or someone you are caring for has a fever that could be malaria, the correct next step is a test and, if needed, a proven antimalarial drug. It is not this page, and it is not this herb.

Back to Table of Contents

What Is Not Known: A Numbered List

  1. No human trial of chiretta alone, at any dose or in any preparation, for fever, malaria, or any other febrile illness.
  2. No human dose-response data for any antipyretic or antiplasmodial endpoint — the traditional 1–3 g/day range used elsewhere on this site’s main Chiretta page has no basis in any measured human fever or parasite outcome.
  3. No identified single constituent responsible for a human antipyretic effect. Swertiamarin’s mouse immune-modulation finding is a real result in a mouse; it has not been shown to be the mechanism behind any human fever response, because no human fever response has been measured.
  4. No trial comparing chiretta, or AYUSH-64, against a first-line antimalarial — an artemisinin-based combination therapy — in any human study design, head-to-head or as an adjunct.
  5. No study of whether using chiretta or AYUSH-64 delays care-seeking for a real fever or a real malaria infection in practice. This is the actual behavioural risk this page warns about, and it has itself never been measured — the safety concern rests on the well-established natural history of malaria, not on any study of herb users’ outcomes.
  6. No human pharmacokinetic data connecting the doses used in the mouse Plasmodium berghei study and the hamster SARS-CoV-2 study to any dose achievable from a traditional chiretta decoction or a standard AYUSH-64 tablet.
  7. No independent replication of the Syrian hamster component-dissection study. It is a well-designed single study assigning antiviral credit to Alstonia scholaris over the other three ingredients; one study, however careful, is not yet a settled literature.
  8. No controlled human trial of AYUSH-64, or of chiretta, that used fever or malaria as its outcome measure. Every controlled, randomised, human data point that exists for this formula was generated against COVID-19 — an indication with no history in any of its four ingredients.

Back to Table of Contents

Verdict and Evidence Tier

Practical reading: there is no version of this evidence that supports reaching for chiretta, or for AYUSH-64, in place of a diagnosis when a fever might be malaria. The strongest human data on this page belongs to an unrelated respiratory virus, generated by a formula whose own component study says chiretta was not the ingredient doing the antiviral work. Treat the classical fever claim as an important, unresolved historical fact about the plant — and treat any dangerous or unexplained fever as what it is: a reason to get tested, not a reason to reach for a bitter herb.

Back to Table of Contents

Key Research Papers

All links are live PubMed searches rather than fixed records, so you can see each return’s size and currency for yourself — and, for the searches flagged above as returning off-target species, see the substitution problem directly.

  1. Ali, “‘Ayush-64’ — a new anti-malarial herbal compound”, Indian Journal of Pathology & Microbiology, 1996 — the primary human malaria record; two pages, no abstract on file.
  2. Willcox, “Improved traditional phytomedicines in current use for the clinical treatment of malaria”, Planta Medica, 2011 — AYUSH-64 is one of six reviewed; a recognition list, not an efficacy meta-analysis.
  3. Patel and colleagues, “Swertiamarin-mediated immune modulation/adaptation confers protection against Plasmodium berghei”, Future Microbiology, 2022 — the one chiretta-specific antiplasmodial finding on this page, in mice.
  4. Rizvi and colleagues, “Evaluation of Ayush-64 (a Polyherbal Formulation) and Its Ingredients in the Syrian Hamster Model for SARS-CoV-2 Infection Reveals the Preventative Potential of Alstonia scholaris”, Pharmaceuticals, 2023 — the component-attribution study this whole page turns on.
  5. Chopra and colleagues, “Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19”, PLoS ONE, 2023 — the largest randomised trial, 140 patients.
  6. Singh and colleagues, “AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: an open-label randomized controlled trial in Chandigarh, India”, Complementary Therapies in Medicine, 2022.
  7. Thakar and colleagues, “Impact of AYUSH 64 as an adjunctive to standard of care in mild COVID 19 — an open-label randomized controlled pilot study”, Journal of Ayurveda and Integrative Medicine, 2022 — the honestly reported null result on the primary outcome.
  8. Thakar and colleagues, “AYUSH Therapeutics for COVID-19: A Living Systematic Review and Meta-Analysis”, Journal of Integrative and Complementary Medicine, 2023 — the pooled, GRADE-rated estimate.
  9. Chaudhari & Somvanshi, “A methodological analysis of CTRI-registered clinical trials on Ayurveda interventions for COVID-19 management”, Journal of Ayurveda and Integrative Medicine, 2023 — the trial-quality caution.
  10. Diantini and colleagues, “Efficacy and Safety of Add-On Plant-Based Drugs for COVID-19 Patients: A Review of the Randomized Control Trials”, Infection and Drug Resistance, 2023 — the wider context in which Andrographis, not chiretta, comes out on top.
  11. Chiretta and antipyretic activity — run it yourself; most of the return is other Swertia species or off-target work.
  12. Malaria rapid diagnostic testing and the cost of delayed treatment — the safety evidence behind this page’s central warning.

Connections

Back to Table of Contents